FDAnews
www.fdanews.com/articles/197884-doj-charges-glenmark-in-ongoing-generic-price-fixing-investigation

DOJ Charges Glenmark In Ongoing Generic Price-Fixing Investigation

July 2, 2020

The Department of Justice (DOJ) has charged Indian drugmaker Glenmark Pharmaceuticals with allegedly conspiring to increase prices on the cholesterol drug pravastin.

The complaint in a Pennsylvania federal court alleges that Glenmark conspired with Apotex and another unnamed company to fix prices for the generic drug from May 2013 to December 2015. The suit alleges that the companies gained $200 million for the scheme.

Glenmark is the fifth company over the past 13 months to be charged as part of a DOJ investigation.

View today's stories